Royal Bank of Canada’s Adicet Bio ACET Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $11K | Sell |
1,699
-3,750
| -69% | -$28.1K | ﹤0.01% | 6117 |
|
|
2025
Q4 | $46K | Buy |
5,449
+442
| +9% | +$4.89K | ﹤0.01% | 5592 |
|
|
2025
Q3 | $65K | Buy |
5,007
+5,001
| +83,350% | +$58.9K | ﹤0.01% | 5711 |
|
|
2025
Q2 | $0 | Buy |
+6
| New | +$63 | ﹤0.01% | 6979 |
|
|
2025
Q1 | – | Sell |
-22
| Closed | – | – | 6760 |
|
|
2024
Q4 | $0 | Buy |
+22
| New | +$415 | ﹤0.01% | 6855 |
|
|
2024
Q3 | – | Sell |
-123
| Closed | -$2K | – | 6783 |
|
|
2024
Q2 | $2K | Buy |
123
+48
| +64% | +$1.29K | ﹤0.01% | 6703 |
|
|
2024
Q1 | $3K | Sell |
75
-492
| -87% | -$20.4K | ﹤0.01% | 6561 |
|
|
2023
Q4 | $17K | Buy |
567
+248
| +78% | +$5.41K | ﹤0.01% | 6353 |
|
|
2023
Q3 | $7K | Buy |
319
+120
| +60% | +$4.24K | ﹤0.01% | 6515 |
|
|
2023
Q2 | $8K | Buy |
199
+92
| +86% | +$8.12K | ﹤0.01% | 6525 |
|
|
2023
Q1 | $10K | Sell |
107
-113
| -51% | -$14.2K | ﹤0.01% | 6298 |
|
|
2022
Q4 | $31K | Buy |
220
+197
| +857% | +$49.2K | ﹤0.01% | 6115 |
|
|
2022
Q3 | $5K | Buy |
23
+13
| +130% | +$3.3K | ﹤0.01% | 6705 |
|
|
2022
Q2 | $2K | Sell |
10
-89
| -90% | -$19.5K | ﹤0.01% | 6911 |
|
|
2022
Q1 | $32K | Sell |
99
-142
| -59% | -$32.7K | ﹤0.01% | 6340 |
|
|
2021
Q4 | $67K | Buy |
241
+59
| +32% | +$10.1K | ﹤0.01% | 6198 |
|
|
2021
Q3 | $23K | Buy |
182
+75
| +70% | +$9.3K | ﹤0.01% | 6622 |
|
|
2021
Q2 | $18K | Buy |
107
+58
| +118% | +$11.8K | ﹤0.01% | 6606 |
|
|
2021
Q1 | $11K | Sell |
49
-9
| -16% | -$2.07K | ﹤0.01% | 6745 |
|
|
2020
Q4 | $13K | Buy |
58
+3
| +5% | +$614 | ﹤0.01% | 6251 |
|
|
2020
Q3 | $10K | Buy |
55
+13
| +31% | +$3.29K | ﹤0.01% | 5917 |
|
|
2020
Q2 | $11K | Sell |
42
-24
| -36% | -$4.72K | ﹤0.01% | 5792 |
|
|
2020
Q1 | $8K | Buy |
66
+26
| +65% | +$3.86K | ﹤0.01% | 5880 |
|
|
2019
Q4 | $6K | Buy |
40
+39
| +3,900% | +$19.7K | ﹤0.01% | 6283 |
|
|
2019
Q3 | $1K | Buy |
+1
| New | +$1.12K | ﹤0.01% | 6378 |
|
|
2019
Q1 | – | Sell |
-1
| Closed | -$1K | – | 6760 |
|
|
2018
Q4 | $1K | Sell |
1
-1
| -50% | -$1.32K | ﹤0.01% | 6536 |
|
|
2018
Q3 | $4K | Buy |
+2
| New | +$2.61K | ﹤0.01% | 6323 |
|
|
2018
Q2 | – | Sell |
-5
| Closed | -$5.38K | – | 6470 |
|
|
2018
Q1 | $5K | Buy |
+5
| New | +$9.17K | ﹤0.01% | 5913 |
|
Other funds holding ACET
RCM
O
VCM
WP
PM
SCM
Royal Bank of Canada's ACET Position: Q1 2026 in Review
Royal Bank of Canada reduced its Adicet Bio (ACET) stake by 69% in Q1 2026, selling an estimated $28.1K and leaving 1,699 shares worth $11K. The position accounts for ﹤0.01% of the portfolio, ranked #6117.
Royal Bank of Canada first reported a position in ACET in Q1 2018 and has held it in 28 quarters since. The position peaked at $67K in Q4 2021. 49 funds tracked by Wall St. Rank hold ACET as of Q1 2026.
- Royal Bank of Canada held 1,699 shares of Adicet Bio worth $11K as of Q1 2026.
- Royal Bank of Canada sold 3,750 Adicet Bio shares in Q1 2026, an estimated $28.1K.
- Adicet Bio made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #6117 holding.
- Royal Bank of Canada first reported a position in Adicet Bio in Q1 2018 and has held it in 28 quarters since.
- Royal Bank of Canada's Adicet Bio position peaked at $67K in Q4 2021.
- 49 funds tracked by Wall St. Rank held Adicet Bio as of Q1 2026.
Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.